AC Immune (ACIU) Cash & Equivalents (2014 - 2025)

AC Immune (ACIU) has 12 years of Cash & Equivalents data on file, last reported at $33.5 million in Q4 2025.

• Quarterly Cash & Equivalents fell 19.04% year-over-year to $33.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $33.5 million (down 19.04% YoY) and the FY2025 annual result came in at $32.3 million, down 21.95% from the prior year.
• Cash & Equivalents slipped to $33.5 million in Q4 2025 per ACIU's latest filing, from $34.7 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $89.2 million in Q4 2021 and bottomed at $101925.1 in Q3 2021.
• The 5-year median for Cash & Equivalents is $39.4 million (2024), against an average of $45.2 million.
• The widest annual swing landed in 2021, when Cash & Equivalents sank 99.95%; it then jumped 74650.25% in 2022.
• Tracing ACIU's Cash & Equivalents over 5 years: stood at $89.2 million in 2021, then sank by 63.23% to $32.8 million in 2022, then jumped by 169.9% to $88.5 million in 2023, then plunged by 53.21% to $41.4 million in 2024, then decreased by 19.04% to $33.5 million in 2025.
• Per Business Quant, the three latest ACIU Cash & Equivalents figures stand at $33.5 million (Q4 2025), $34.7 million (Q3 2025), and $43.8 million (Q2 2025).

Peer Comparison